|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
oral syringe
|
|
gptkbp:age
|
infants
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:J07BH01
|
|
gptkbp:broadcastOn
|
two doses
|
|
gptkbp:contains
|
gptkb:live_attenuated_human_rotavirus_strain_G1P[8]
|
|
gptkbp:contraindication
|
gptkb:severe_combined_immunodeficiency_(SCID)
severe allergic reaction to previous dose
history of intussusception
|
|
gptkbp:countryOfOperation
|
over 100 countries
|
|
gptkbp:firstDoseAge
|
6 weeks
|
|
gptkbp:form
|
oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rotarix
|
|
gptkbp:indication
|
rotavirus gastroenteritis
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:pregnancyCategory
|
not applicable
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:protectionDuration
|
at least 3 years
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:secondDoseAge
|
at least 4 weeks after first dose
|
|
gptkbp:sideEffect
|
diarrhea
irritability
intussusception (rare)
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:type
|
live attenuated vaccine
|
|
gptkbp:usedFor
|
prevention of rotavirus infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Rotavirus
|
|
gptkbp:bfsLayer
|
5
|